Key takeaway: OneSource Specialty Pharma Limited reported strong financial results for Q1 FY27, with revenues of INR 4,490 million, reflecting a 37% year-on-year growth. Management attributed this growth to the successful commercial launch of semaglutide, new MSA contracts, and customer acquisitions. EBITDA increased by 39% year-on-year to INR 1,233 million. The company highlighted its significant market presence in Canada and India, with over 40% of the generic pens market in India being manufactured at its site. Management noted that despite temporary supply disruptions from a partner, their capacity utilization remains high due to a diverse customer base. The company is also expanding its capacity with a new cartridge line and plans for further growth in biologics and drug-device combinations. Management reiterated its FY28 revenue goal of $400 million and EBITDA margins of 40%.

Key takeaway: OneSource Specialty Pharma Limited reported its Q4FY26 results, highlighting a 47% quarter-on-quarter increase in revenue to ₹4,282 million, driven by growth across all service offerings and the commercial launch of semaglutide in India. EBITDA expanded more than fivefold to ₹919 million, reflecting operating leverage from higher revenues. The adjusted PAT was reported at ₹390 million, with an adjusted EPS of ₹3.4. For FY26, the company reaffirmed its guidance of approximately $400 million in organic revenue with a ~40% EBITDA margin. CEO Neeraj Sharma noted a strong recovery in Q4, supported by successful product launches and approvals in multiple markets. The company also emphasized its ongoing capacity expansion and the growth potential in its biologics and injectables segments, while addressing the pause in a proposed acquisition of specialty injectable assets.

Key takeaway: OneSource Specialty Pharma Limited's Q3 FY '26 earnings call highlighted revenue deferrals due to delayed Canadian regulatory approvals for semaglutide, impacting Q3 results. Management emphasized strategic focus on capacity expansion and commercial readiness, with FY '28 guidance of $400 million revenue and $160 million EBITDA. Operational highlights included sterile facility upgrades in Bangalore and progress in biologics, driven by favorable FDA guidelines and the Biosecure Act. Financials showed a 26% YoY revenue decline to INR2,903 million and an EBITDA of INR173 million, with adjusted PAT at a loss of INR472 million. Management noted temporary working capital increases due to inventory buildup for upcoming launches, expecting normalization by FY '27. Credit rating upgrades reduced interest costs, and capex funding was secured through partnerships. The company remains confident in long-term growth, with capacity expansion on track and customer demand robust despite near-term challenges.